Ozempic in North Carolina (2026)
semaglutide · GLP-1 weight management · North Carolina
About Ozempic
FDA-approved semaglutide for type 2 diabetes. Widely used off-label for weight loss.
See the full Ozempic review for dosing, efficacy data, side effects, and the full pharmacy + telehealth program comparison.
Insurance coverage for Ozempic in North Carolina
NC Medicaid covers GLP-1s for weight management with prior authorization (criteria effective August 1, 2024). Coverage was paused on October 1, 2025 and reinstated on December 12, 2025. Wegovy is the preferred drug; Zepbound and Saxenda require a trial of Wegovy first.
| Carrier | Ozempic status | Detail |
|---|---|---|
| Aetna | Covered | Ozempic is FDA-approved for type 2 diabetes, not for weight loss. We have not found a public Aetna coverage document for Ozempic, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card. |
| Blue Cross Blue Shield | Covered (prior auth required) | When Blue Cross Blue Shield of Massachusetts ended weight-loss GLP-1 coverage in 2026, it kept coverage of GLP-1s approved for type 2 diabetes, including Ozempic, Mounjaro and Trulicity. They still require prior authorization that includes a documented diabetes diagnosis. Other Blue plans set their own rules. |
| UnitedHealthcare | Covered | Ozempic is FDA-approved for type 2 diabetes, not for weight loss. We have not found a public UnitedHealthcare coverage document for Ozempic, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card. |
| Cigna | Covered | Ozempic is FDA-approved for type 2 diabetes, not for weight loss. We have not found a public Cigna coverage document for Ozempic, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card. |
| Humana | Covered | Medicare Part D, including Humana drug plans, covers Ozempic for type 2 diabetes. Check Humana's formulary for your plan's tier and prior authorization rules. |
| Kaiser Permanente | Covered | Ozempic is FDA-approved for type 2 diabetes, not for weight loss. We have not found a public Kaiser Permanente coverage document for Ozempic, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card. |
| Anthem | Covered | Ozempic is FDA-approved for type 2 diabetes, not for weight loss. We have not found a public Anthem commercial coverage document for Ozempic, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card. |
| Medicare | Covered | Part D plans cover Ozempic for type 2 diabetes; tier and prior authorization depend on your plan's formulary. People with type 2 diabetes get GLP-1s through their Part D plan and cannot use the Medicare GLP-1 Bridge. |
| Medicaid | Covered | MassHealth lists Ozempic as a preferred GLP-1 for diabetes, and California Medi-Cal keeps Ozempic on its drug list restricted to type 2 diabetes. Neither covers it for weight loss. |
| TRICARE | Covered (prior auth required) | TRICARE covers Ozempic for type 2 diabetes for all beneficiaries, including TRICARE For Life, with prior authorization. A medical necessity form is also required for the formulary copayment and for coverage at a military pharmacy. The Wegovy/Zepbound form does not approve those drugs for diabetes. |
Telehealth and prescribing in North Carolina
A telehealth clinician must be licensed in North Carolina to prescribe Ozempic to you while you are in North Carolina.
North Carolina joined the Interstate Medical Licensure Compact effective January 1, 2026 (Session Law 2025-37).
- Source: NC Medical Board: IMLC
Platforms differ in which drugs they prescribe, insurance handling, and clinical model. See our platform comparisons.
Compounded semaglutide
On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.
Ozempic in North Carolina: common questions
Is Ozempic legal in North Carolina?+
Yes. Ozempic (semaglutide) is FDA-approved and legal in all 50 US states including North Carolina. State-level differences appear in Medicaid coverage and clinician licensing, not in the legality of the medication itself.
Can I get Ozempic via telehealth in North Carolina?+
Yes, from a clinician licensed in North Carolina. A telehealth clinician must be licensed in North Carolina to prescribe Ozempic to you while you are in North Carolina. North Carolina joined the Interstate Medical Licensure Compact effective January 1, 2026 (Session Law 2025-37).
Does North Carolina Medicaid cover Ozempic?+
Covered with prior authorization for weight loss. NC Medicaid covers GLP-1s for weight management with prior authorization (criteria effective August 1, 2024). Coverage was paused on October 1, 2025 and reinstated on December 12, 2025. Wegovy is the preferred drug; Zepbound and Saxenda require a trial of Wegovy first.
What's the cheapest way to get Ozempic in North Carolina?+
The main paths are insurance with prior authorization if your plan covers it, manufacturer cash-pay programs, or telehealth programs that include the medication. NovoCare Pharmacy sells Wegovy pens to cash-pay patients for $349 a month ($199 a month for the first two months for new patients through December 31, 2026). LillyDirect sells Zepbound vials for $299 (2.5 mg), $399 (5 mg), and $449 (7.5 to 15 mg) a month when refilled on time.
Is compounded Ozempic still available in North Carolina?+
Compounding rules are federal, not set by North Carolina. On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.